Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P78364
UPID:
PHC1_HUMAN
Alternative names:
Early development regulatory protein 1
Alternative UPACC:
P78364; D3DUV4; Q8WVM3; Q9BU63
Background:
Polyhomeotic-like protein 1, also known as Early development regulatory protein 1, plays a crucial role in gene repression through the Polycomb group (PcG) multiprotein PRC1-like complex. This complex is essential for maintaining the transcriptionally repressive state of numerous genes, including Hox genes, across development stages. It achieves this by mediating monoubiquitination of histone H2A 'Lys-119', which alters chromatin expressibility.
Therapeutic significance:
Polyhomeotic-like protein 1's involvement in Microcephaly 11, a condition characterized by significantly reduced brain size and cerebral cortex, highlights its potential as a target for therapeutic intervention. Understanding the role of Polyhomeotic-like protein 1 could open doors to potential therapeutic strategies.